Are deep brain stimulation for psychiatric disorders ready for clinical or public health use?

Which psychiatric disorders have the strongest evidence for DBS?

The strongest evidence for DBS in psychiatry is for obsessive-compulsive disorder (OCD) and Tourette's syndrome. OCD is the only psychiatric condition with FDA approval for DBS in the U.S. [5]. Across studies, DBS for treatment-resistant OCD produces response and remission rates approaching 48% and 35%, respectively [2]. For Tourette's syndrome, a recent NIH-funded trial of 10 patients found that 4 out of 8 (50%) who received chronic responsive DBS achieved a 30% or greater reduction in motor tic severity at 6 months [1]. These figures show meaningful improvement in patients who have exhausted other options, but they also mean that roughly half of patients do not respond well.

For other conditions, the evidence is more preliminary. In substance use disorders, a systematic review of 26 studies (71 patients) found that DBS targeting the nucleus accumbens reduced cravings and consumption, but 73.2% of patients still relapsed [4]. For depression, response rates are around 48% in open-label studies, but randomized controlled trials have struggled to meet their endpoints [2][7]. Data for bipolar disorder, schizophrenia, anorexia nervosa, and post-traumatic stress disorder are encouraging but limited by very small sample sizes and inconsistent methods [2].

What are the main barriers to wider use?

A major barrier is that DBS has not consistently outperformed sham or placebo in controlled trials, even when open-label results look strong. For example, in depression and OCD, early open-label studies showed high response rates, but later randomized controlled trials failed to meet their primary endpoints [2][7]. This suggests that part of the benefit may be a placebo effect, or that current methods for selecting patients and setting stimulation parameters are not yet optimal.

Safety and ethical concerns also limit adoption. Surgical risks include infection, bleeding, and hardware problems, and psychiatric side effects like hypomania, apathy, and impulse control disorders can occur [8]. There are also ethical challenges around informed consent in patients with severe mental illness, and concerns about effects on personal identity [8]. A survey of French psychiatrists found that the most important factor in their acceptance of DBS was whether it was endorsed by professional guidelines, not just the evidence of efficacy [6]. This highlights that clinical integration depends on institutional validation as much as on data.

Technically, DBS is still a 'one-size-fits-all' approach in many cases. Clinicians have many adjustable parameters but little feedback on whether they have chosen correctly for a given patient [7]. New 'closed-loop' systems that sense brain activity and adjust stimulation automatically are being tested, but they are not yet ready for routine use [1][7].

Who might benefit from DBS, and under what conditions?

DBS is currently appropriate only for patients with severe, treatment-resistant psychiatric disorders who have exhausted standard therapies. For OCD, this means patients who have not responded to multiple medication trials and intensive cognitive-behavioral therapy [5]. For Tourette's, it is for those with debilitating tics that do not respond to medication or behavioral therapy [1][10]. The decision requires a multidisciplinary team including psychiatrists, neurosurgeons, and neuropsychologists [9].

Even in these carefully selected groups, outcomes vary. In the Tourette's trial, half of patients responded, but the other half did not [1]. In OCD, about a third of patients achieve remission [2]. This means that DBS is not a cure, and patients and families need realistic expectations. Long-term data on quality of life are limited [2], and the cost and complexity of the procedure mean it is unlikely to have a major public health impact for common conditions like addiction [4].

The evidence does not support DBS for general psychiatric use. It remains an investigational therapy for most conditions, and even for FDA-approved OCD, it is a specialized, last-resort option. The field is moving toward better patient selection using brain imaging [3] and more personalized stimulation [7], but these advances are not yet ready for widespread clinical adoption.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2023 to 2026, 9 from 2024 or later, 4 in Q1 journals, collectively cited 51 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 72 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions